A Multiple-dose, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCQ908 in Patients With Severe Hypertriglyceridemia and Chylomicronemia (Phenotypes I and V).
Phase of Trial: Phase I/II
Latest Information Update: 31 Dec 2012
At a glance
- Drugs Pradigastat (Primary)
- Indications Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type V
- Focus Biomarker; Pharmacodynamics
- 03 May 2012 Actual patient number 8 added as reported by ClinicalTrials.gov.
- 03 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jul 2011 Planned End Date changed from 1 Nov 2010 to 1 Oct 2011 as reported by ClinicalTrials.gov.